StockStory Favors Boston Scientific (BSX) Over Zoominfo (GTM), Matthews (MATW) on Valuation Concerns

StockStory, an independent research firm, on May 29, 2026, highlighted Boston Scientific (NYSE:BSX) as a value pick while urging caution on Zoominfo (NASDAQ:GTM) and Matthews International (NASDAQ:MATW), despite consensus price targets implying returns above 20% for all three. Boston Scientific, trading at $49.18 per share with a forward price-to-earnings ratio of 14.6, garnered a target of $80.16 (63% implied upside). StockStory endorsed its fundamentals. In contrast, Zoominfo at $3.28 (0.8 times forward sales) and Matthews at $27.05 (0.7 times trailing sales) were flagged as overhyped, with the firm noting low multiples do not automatically signal value given underlying business challenges. The analysis cautioned that Wall Street price targets can be inflated by conflicts of interest, as analysts may issue positive ratings to win advisory work.